Skip to search formSkip to main contentSkip to account menu

Fibrinolytic Agents

Known as: thrombolytic drug, [BL115] THROMBOLYTICS, Thrombolytic Drugs 
Any agent capable of dissolving an existing blood clot in order to reperfuse the blocked blood vessel.
National Institutes of Health

Related topics

Related topics

46 relations

Narrower (41)

9-O-methanoprostaglandin IAncrodAnistreplaseAspirin
Antithrombotic AgentsFibrinolysisIn BloodProtein C

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy.
BACKGROUND Left ventricular (LV) remodeling after acute myocardial infarction has still to be clarified in the thrombolytic era… 
Highly Cited
1994
Highly Cited
1994
Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial.
BACKGROUND Acute closure is increased after angioplasty in unstable angina, and adjunctive intracoronary thrombolytic therapy has… 
Highly Cited
1993
Highly Cited
1993
Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Highly Cited
1993
Highly Cited
1993
Significance of diabetes mellitus in patients with acute myocardial infraction receiving thrombolytic theraphy
Highly Cited
1990
Highly Cited
1990
Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty.
Highly Cited
1989
Highly Cited
1989
Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator.
Ischemic events after successful thrombolysis have been reported to occur in 18-32% of patients treated for acute myocardial… 
Highly Cited
1989
Highly Cited
1989
Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Fibrinopeptide A (FPA) is a very sensitive marker of fibrin generation in vivo. Because an imbalance between thrombogenic and… 
Highly Cited
1988
Highly Cited
1988
Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a non-invasive marker.
The predictive value of the measurement of changes in ST segment elevation was assessed as a non-invasive marker of coronary… 
Highly Cited
1982
Highly Cited
1982
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
Extrinsic (tissue-type) plasminogen activator (plasminogen activator) was isolated either as a single-chain or as a two-chain… 
Highly Cited
1975
Highly Cited
1975
Prostaglandin d2 as a potential antithrombotic agent.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)